Clinical studies in COVID-related olfactory disorders:Review of an institutional experience  

作　　者：Theresa Tharakan Dorina Kallogjeri Jay F.Piccirillo 

机构地区：[1]Department of Otolaryngology-Head and Neck Surgery,Clinical Outcomes Research Office,School of Medicine,Washington University in St Louis,St Louis,Missouri,USA

出　　处：《World Journal of Otorhinolaryngology-Head and Neck Surgery》2024年第2期129-136,共8页世界耳鼻咽喉头颈外科杂志（英文）

基　　金：National Institute on Deafness and Other Communication Disorders,Grant/Award Number:T32DC000022。

摘　　要：Objective:To share a single institutional experience with clinical research on COVID-related olfactory dysfunction(OD).Data Source/Method:Narrative review of published original data and ongoing clinical trials on COVID-related OD at Washington University from 2020 to 2023.Results:There were three new diagnostic-/patient-reported outcome measures developed and tested.We report five clinical trials of interventions for COVID-related olfactory disorders:combined Visual-Olfactory Training(VOLT)with patient-preferred scents versus standard olfactory training(VOLT trial),oral gabapentin versus placebo(Gabapentin for the Relief of Acquired Chemosensory Experience trial),nasal theophylline irrigations versus placebo(Smell Changes and Efficacy of Nasal Theophylline trial),stellate ganglion block(single-arm),and mindfulness-based stress reduction(MBSR)versus lifestyle intervention(MBSR trial).Conclusions:Initial intervention trials for COVID-related OD have shown potential for improving subjective and objective olfactory outcomes.However,there remains no gold standard treatment that definitively outperforms placebo in controlled trials.Therefore,continued investigation of novel therapeutic strategies for COVID-related OD is necessary to maximize olfactory outcomes for affected patients.

关 键 词：chemosensory disorders COVID olfactory dysfunction 

分 类 号：R511[医药卫生—内科学]